Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745383 | 0.87 | — | — | |
| SCHEMBL20280308 | 0.77 | — | — | |
| SCHEMBL34979 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL4048080 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL670620 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL17583500 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL980620 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL671851 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL5803239 | 0.73 | USP2 (0.54) | USP2ALDH1A1LMNACYP1A2TSHR | |
| Ammonia Solution, Strong SCHEMBL5039681 | 0.73 | USP2 (0.54) | USP2ALDH1A1LMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| US-20220072006-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2022-03-10 | — | — | US | disclosed |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210078962-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-03-18 | — | — | US | disclosed |
| US-10844026-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200157069-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-05-21 | — | — | US | disclosed |
| US-10562870-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2019-07-23 | — | — | US | disclosed |
| US-20170334870-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2017-11-23 | — | — | US | disclosed |
| US-20170334870-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2017-11-23 | — | — | US | disclosed |
| US-9725427-B2 | Prodrugs of riluzole and their method of use | Biohaven Pharmaceutical Holding Company Limited (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725427-B2 | Prodrugs of riluzole and their method of use | Biohaven Pharmaceutical Holding Company Limited (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2015-02-12 | — | — | US | disclosed |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, CYP3A5, UGT1A1 | USP2 96/4885ALDH1A1 45/4885LMNA 202/4885 |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, UGT1A1, SMN1; SMN2 | USP2 85/4885ALDH1A1 50/4885LMNA 319/4885 |
| US-20170334870-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | USP2 151/4885ALDH1A1 9/4885LMNA 3160/4885 |
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | USP2 151/4885ALDH1A1 9/4885LMNA 3160/4885 |
| US-20210078962-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | USP2 151/4885ALDH1A1 9/4885LMNA 3160/4885 |
| US-10844026-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | USP2 151/4885ALDH1A1 9/4885LMNA 3160/4885 |
| US-10562870-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | USP2 151/4885ALDH1A1 9/4885LMNA 3160/4885 |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | USP2 151/4885ALDH1A1 9/4885LMNA 3160/4885 |
| US-20220072006-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CYP1A2, CYP3A5, UGT1A1 | USP2 96/4885ALDH1A1 45/4885LMNA 202/4885 |
| US-20200157069-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | USP2 151/4885ALDH1A1 9/4885LMNA 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.